The effect of esomeprazole 40mg once or twice daily on asthma outcome

T. Kiljander, O. Junghard, O. Beckman, T. Lind (Turku, Finland; Mölndal, Sweden)

Source: Annual Congress 2009 - Aspects of clinical asthma
Session: Aspects of clinical asthma
Session type: Thematic Poster Session
Number: 1967
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
T. Kiljander, O. Junghard, O. Beckman, T. Lind (Turku, Finland; Mölndal, Sweden). The effect of esomeprazole 40mg once or twice daily on asthma outcome. Eur Respir J 2009; 34: Suppl. 53, 1967

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Comparable efficacy of ciclesonide 160 μg once daily and budesonide 200 μg twice daily in patients with asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 254s
Year: 2005

Once daily ciclesonide (80 µg or 320 µg) is equally effective as budesonide 200 µg given twice daily: a 12-week study in asthma patients
Source: Eur Respir J 2003; 22: Suppl. 45, 410s
Year: 2003

Inhaled budesonide 800 μg once daily versus 400 μg twice daily in patients with mild-to-moderate asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 97s
Year: 2001

Ciclesonide once daily (80 mg/d, 160 mg/d) versus fluticasone propionate twice daily (250 mg/d) in the treatment of patients with persistent asthma
Source: Annual Congress 2010 - Treatment options for asthma
Year: 2010

Ciclesonide 80 μg or 160 μg once daily is comparable to fluticasone propionate 88 μg twice daily in the treatment of asthma patients
Source: Eur Respir J 2005; 26: Suppl. 49, 255s
Year: 2005

Comparison of 800 μg once vs. 400 μg twice daily inhaled budesonide in patients with moderate asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 49s
Year: 2001

Efficacy of the novel very long-acting β2-agonist carmoterol following 7 days once daily dosing: comparison with twice daily formoterol in patient with persistent asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 665s
Year: 2006

Ciclesonide 160 μg once daily compared with fluticasone propionate 250 μg twice daily in maintenance therapy of patients with stable asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 205s
Year: 2006

Comparison of ciclesonide once daily (80 μg/d, 160 μg/d) and fluticasone propionate twice daily (176 μg/d) in the treatment of children with persistent asthma
Source: Eur Respir J 2007; 30: Suppl. 51, 457s
Year: 2007

The effect of two month's treatment with fluticasone (F) at a dose of 500 mg per day versus fluticasone at a dose of 250 mg per day plus salmeterol (S) 100 mg per day in patients with moderate asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 302s
Year: 2002

The salmeterol/fluticasone propionate combination 50/100 μg bid is more effective than oral montelukast 10 mg od as a first line therapy in mild and moderate asthmatics
Source: Eur Respir J 2001; 18: Suppl. 33, 262s
Year: 2001

Comparable efficacy and tolerability of formoterol 12 μg or 24 μg twice daily in asthma patients
Source: Eur Respir J 2005; 26: Suppl. 49, 51s
Year: 2005

Once daily ciclesonide and twice daily fluticasone propionate are equally effective in the treatment of patients with asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 346s
Year: 2004

Effects of esomeprazole 40 mg twice-daily in adults with moderate to severe asthma who had been treated previously with inhaled steroids and long-acting β2-agonists
Source: Eur Respir J 2005; 26: Suppl. 49, 278s
Year: 2005

Efficacy of esomeprazole 40 mg twice daily for 16 weeks in adults with asthma: a randomised placebo-controlled trial
Source: Eur Respir J 2005; 26: Suppl. 49, 278s
Year: 2005

Salmeterol/fluticasone propionate combination 50/100 μg bid is more effective than fluticasone propionate 100 μg bid plus montelukast 10 mg once daily in reducing exacerbations
Source: Eur Respir J 2001; 18: Suppl. 33, 262s
Year: 2001

Safety and tolerability of the novel very long acting β2-agonist Carmoterol given as a 2μg qd dose; 8 days comparison with formoterol and placebo in patients with persistent asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 665s
Year: 2006

A comparison of the efficacy of low dose single inhaler budesonide/formoterol given once and twice daily in patients with mild- to- moderate asthma
Source: Eur Respir J 2007; 30: Suppl. 51, 615s
Year: 2007

Erdosteine 600mg, but not placebo and NAC 1200mg, restores airway response to inhaled salbutamol 200mcg in COPD
Source: Annual Congress 2007 - Mechanisms and new treatments of COPD
Year: 2007


No evidence for increase in serious asthma exacerbations with formoterol 24 μg twice daily
Source: Eur Respir J 2005; 26: Suppl. 49, 51s
Year: 2005